189882-33-5

Basic information

• Product Name: 1H-PYRROLO[2,3-B]PYRIDINE-6-CARBONITRILE
• Synonyms: 1H-PYRROLO[2,3-B]PYRIDINE-6-CARBONITRILE;6-CYANO-7-AZAINDOLE;1H-Pyrrolo[2,3-b]pyridine-6-carbonitrile(9CI);6-Cyano-1H-pyrrolo[2,3-b]pyridine;PYRROLO[2,3-B]PYRIDINE-6-CARBONITRILE
• CAS NO: 189882-33-5
• Molecular Formula: C₈H₅N₃
• Molecular Weight: 143.15
• EINECS: 251-156-6
• Product Categories: PYRIDINE;Azaindoles
• Mol File: 189882-33-5.mol
• Article Data: 13

Chemical Properties

• Melting Point: 187.4 °C
• Boiling Point: 373.2 °C at 760 mmHg
• Flash Point: 127.3 °C
• Appearance: /
• Density: 1.34 g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.685
• Storage Temp.: 2-8°C
• PKA: 6.56±0.40(Predicted)
• CAS DataBase Reference: 1H-PYRROLO[2,3-B]PYRIDINE-6-CARBONITRILE(CAS DataBase Reference)
• NIST Chemistry Reference: 1H-PYRROLO[2,3-B]PYRIDINE-6-CARBONITRILE(189882-33-5)
• EPA Substance Registry System: 1H-PYRROLO[2,3-B]PYRIDINE-6-CARBONITRILE(189882-33-5)

Safety Data

• Hazardous Substances Data: 189882-33-5(Hazardous Substances Data)

Usage

Chemical Properties

Class white powder

InChI:InChI=1/C8H5N3/c9-5-7-2-1-6-3-4-10-8(6)11-7/h1-4H,(H,10,11)

Upstream product

• 143468-13-7 6-Bromo-1H-pyrrolo<2,3-b>pyridine 
• 271-63-6 7-Azaindole 
• 557-21-1 zinc(II) cyanide 
• 151-50-8 potassium cyanide 
• 7677-24-9 trimethylsilyl cyanide 
• 55052-24-9 1H-Pyrrolo[2,3-b]pyridine-7-oxide 
• 143468-07-9 6-Chloro-1-methoxycarbonyl-1H-pyrrolo<2,3-b>pyridine 
• 143468-08-0 1-Benzoyl-6-cyano-1H-pyrrolo<2,3-b>pyridine 

Downstream Products

• 942261-75-8 phenyl(1H-pyrrolo[2,3-b]pyridine-6-yl)methanone 
• 1218906-88-7 1-trityl-4-imidazolecarboxaldehyde 
• 898746-35-5 1H-pyrrolo[2,3-b]pyridine-6-carboxylic acid 
• 1190318-91-2 C₈H₄IN₃ 

Relevant articles and documents

Preparation method of 6-cyano-7-azaindole and derivative thereof

The invention discloses a preparation method of 6-cyano-7-azaindole and a derivative thereof, which comprises the following steps: dissolving a compound represented by formula (1) in a solvent, and performing a reaction with an organic alkali and a cyaniding reagent under the action of a catalyst to obtain the final product represented by formula (2). According to the process disclosed by the invention, the safe and non-toxic potassium ferrocyanide is used as a cyano source, the reaction operation is simple and convenient, the yield is high, the influence on the environment is relatively small, and the process is suitable for preparing the 6-cyano-7-azaindole and the derivative 1-benzoyl-6-cyano-7-azaindole thereof on a large scale.

INHIBITORS OF CYCLIN DEPENDNT KINASE 7 (CDK7)

The present invention provides novel compounds of Formula (I) and pharmaceutically acceptable salts, solvates, hydrates, tautomers, stereoisomers, isotopically labeled derivatives, and compositions thereof. Also provided are methods and kits involving the compounds or compositions for treating or preventing proliferative diseases (e.g., cancers (e.g., leukemia, melanoma, multiple myeloma), benign neoplasms, angiogenesis, inflammatory diseases, autoinflammatory diseases, and autoimmune diseases) in a subject. Treatment of a subject with a proliferative disease using a compound or composition of the invention may inhibit the aberrant activity of cyclin-dependent kinase 7 (CDK7), and therefore, induce cellular apoptosis and/or inhibit transcription in the subject.

ARYLOXYACETYLINDOLES AND ANALOGS AS ANTIBIOTIC TOLERANCE INHIBITORS

The disclosure provides compounds and pharmaceutical compositions of aryloxyacetylindoles compounds and analogs useful for treating chronic and acute bacterial infections. Certain of the compounds are compounds of general Formula (I) (I) or a pharmaceutically acceptable salt or prodrug thereof. Certain compounds of this disclosure are MvfR inhibitors. MvfR inhibitors reduce the formation of antibiotic tolerant bacterial strains and are useful for treating Gram-negative bacterial infections and reducing the virulence of Pseudomonas aeruginosa. Methods of treating bacterial infections in a subject, including Pseudomonas aeruginosa infections, are also provided by the disclosure.